Delving into the unknowns of mRNA-LNP formulation and characterization

As nanoparticle-based delivery systems continue to gain traction in the nucleic acids space, the need to address lingering issues, such as stability, becomes ever more pressing. David McCall, Senior Editor, BioInsights, asks Ramesh Marasini, Scientist, Lead, mRNA–LNP Drug Product Development with CAMRIS International LLC at the Pilot Bioproduction Facility, Walter Reed Army Institute of Research (WRAIR), for his thoughts on the key knowledge gaps threatening to impede the continued growth of the field.

Please enter your email to access content Read now